Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Nanomedicine. 2018 Nov 22;18:414–425. doi: 10.1016/j.nano.2018.11.005

Figure 1. Antigen and nanoparticle design.

Figure 1.

(A) Illustration of ZEBOV envelope glycoprotein (GP) displayed on the viral envelope as a native trimer (red brackets indicate the GP1/GP2 disulfide bond). (B) Illustration recombinant modifications to produce rGP (TM, transmembrane domain). (C) Diagram of expected rGP display on an ICMV or NTA ICMV (DTT, dithiothreitol).